IPN.PA - Ipsen S.A.
Ipsen S.A.
65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers—Specialty & Generic
Employés à temps plein: 5 072
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. David Loew | MD, CEO & Director | 2,22M | S.O. | 1967 |
| Mr. Aymeric Le Chatelier | Exec. VP & Group CFO | S.O. | S.O. | 1969 |
| Dr. Aidan Murphy Ph.D. | Exec. VP of Technical Operations | S.O. | S.O. | 1966 |
| Mr. Craig Marks | Vice-Pres of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Francois Garnier | Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer | S.O. | S.O. | 1962 |
| Ms. Gwenan White | Exec. VP of Communications, Public Affairs & Sustainability | S.O. | S.O. | S.O. |
| Mr. Regis Mulot | Exec. VP & Chief HR Officer | S.O. | S.O. | 1966 |
| Ms. Dominique Bery | Head of Nordics & Baltics | S.O. | S.O. | 1971 |
| Dr. Yan Moore M.D. | Sr. VP & Head of Oncology Therapeutic Area | S.O. | S.O. | 1967 |
| Dr. Alexander McEwan | Vice-Pres & Head of Radiopharmaceuticals | S.O. | S.O. | S.O. |
Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Ipsen S.A. en date du 1 juin 2023 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 7; Compensation : 6.
